Miami’s cosmetic-surgery boom draws Swiss dermatology group Galderma

About 200 employees will eventually work from Galderma’s new Miami base, giving the Swiss dermatology company a larger platform in the Americas and a direct foothold in one of the world’s busiest cosmetic procedure markets.

Galderma has taken a full floor at 801 Brickell Avenue, in Miami’s financial district. The company has begun with about 50 staff, while its previous office was much smaller. The expansion reflects the growing weight of the United States in Galderma’s business and the city’s role as a meeting point for affluent residents, international patients and medical specialists.

The Zug based company, valued at about CHF 39 billion, sells injectable aesthetic products as well as prescription medicines for skin conditions. Its US revenue rose by more than 30% in the first half of 2026 from a year earlier. Chief executive Flemming Ornskov has said US sales could soon overtake the company’s international business.

For Switzerland, the move marks another step in the globalisation of a company with deep local roots. Galderma’s commercial momentum is increasingly being built around American demand, while research, manufacturing and corporate ties continue to connect the business to Europe.

More than 30% US revenue growth in the first half of 2026 has made America Galderma’s fastest expanding market and sharpened the case for a larger local operation.

The company already maintains offices in Boston, California and Texas. Miami offers a different advantage. It places executives close to consumers and clinics in South Florida, while providing access to Latin America, a region with strong links to the city’s business and medical communities.

Galderma plans to invest $650 million in US manufacturing through 2030. That commitment points to a strategy that reaches beyond sales offices. The company is building capacity in the market where it expects demand to keep rising, reducing its reliance on a distant supply chain and supporting the growth of its aesthetics portfolio.

Galderma’s expansion follows a powerful run for investors. Since its initial public offering in 2024, the shares have returned 157%, compared with 29% for the SPI. L’Oréal holds a 20% stake. The figures help explain why the company is willing to expand its US infrastructure while it continues to scale its consumer and medical businesses.

Miami’s cosmetic procedure market draws wealthy newcomers and international patients from Latin America and Europe. That combination has increased demand for premium aesthetic treatments, including injectable products sold by Galderma.

South Florida attracted affluent residents during the pandemic through its lifestyle and remote work appeal. Tax differences later added to the pull, as some wealthy households considered moving away from states weighing higher levies on high earners. Tourists with substantial spending power have added another layer of demand.

Ornskov described Miami as a city moving up the ladder in plastic surgery and injectable aesthetics. Medical tourism is central to that assessment. Patients who travel for treatment bring demand to clinics, hotels, specialist practices and the suppliers that serve them.

The market also carries medical risks. Swissinfo reported in July 2026 that Galderma was training thousands of doctors as concerns grew about poorly performed injections and botched procedures. The company’s presence therefore involves more than selling products. Training, practitioner standards and patient safety have become part of the commercial environment surrounding the Botox boom.

The University of Miami gives Galderma a scientific reason to deepen its presence in South Florida. The university is recognised as a major centre for itch research, an area that connects directly to the company’s prescription dermatology business.

Galderma markets medicines such as Nemluvio for conditions that cause itchy skin. The Miami office will therefore sit near a research ecosystem relevant to both sides of the company: consumer aesthetics and medical dermatology. That proximity can support relationships with clinicians, researchers and teaching institutions.

The connection matters because Galderma is not solely an injectable aesthetics company. Its portfolio spans prescription treatments, skin care and aesthetic products. The Miami strategy uses the city’s commercial profile while also drawing on its medical expertise.

The company’s choice reflects a broader pattern in healthcare. Location decisions increasingly combine access to customers with access to scientific talent. Miami offers international connectivity and a large private medical sector, while the University of Miami adds research credibility. For a Swiss company seeking US growth, that mix strengthens the case for keeping senior teams close to the market.

Galderma’s Miami expansion will test how far a Swiss dermatology group can scale an aesthetics business while maintaining medical standards. The company was founded in 1981 as a joint venture between Nestlé and L’Oréal, later became fully owned by Nestlé, and was acquired by investors in 2019 before its 2024 stock market debut.

Its international growth creates opportunities for Swiss investors and employees, but it also highlights the separation between where products are developed, where procedures take place and where complications are treated. Swissinfo has previously reported that complications from cosmetic surgery abroad can place an additional burden on the Swiss health system when patients return home for care.

Miami’s model depends on continuous travel. Affluent residents, visitors from Europe and patients from Latin America support clinics and suppliers, while Galderma’s new office gives the company a permanent base in that network. The planned workforce expansion from 50 employees to about 200 will show whether the city can become a lasting operational centre rather than simply a sales outpost.

For Galderma, the next phase will combine US manufacturing, medical education and product demand. For Switzerland, the company’s rise offers a clear example of how a domestically rooted healthcare business is competing on a global stage.